Verona Pharma plc
("Verona Pharma" or the "Company")
Directorate Change
11 January 2016, Cardiff - Verona Pharma plc (AIM: VRP.L), the drug development
company focused on first-in-class medicines to treat respiratory diseases,
announces the resignation of Biresh Roy, Chief Financial Officer of the
Company. He will step down from the Board with immediate effect but will remain
with Verona Pharma for up to six months to allow time for a suitable successor
to be appointed and for an orderly handover. The Board has commenced a search
for his successor and a further announcement will be made in due course.
Dr. David Ebsworth, Chairman of Verona Pharma, said: "The Board would like to
thank Biresh for his many contributions to the Company. This has been a
particularly formative time for Verona Pharma as it has delivered on important
operational and clinical goals it set at the time of the 2014 Financing in a
timely manner. Importantly, Biresh's financial stewardship has also ensured
that these goals have been met on, or ahead of, budget. We warmly wish Biresh
all the best in his future endeavours."
-Ends-
For further information please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive
Officer
N+1 Singer Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
FTI Consulting Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company
focused on the development of innovative prescription medicines to treat
respiratory diseases with significant unmet medical needs, such as chronic
obstructive pulmonary disease (COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase
II trials as a nebulised treatment for acute exacerbations of COPD in the
hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and
therefore has both bronchodilator and anti-inflammatory effects, which are
essential to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of RPL554-containing
products to maximise its benefit to patients and its value. This includes the
very significant markets for COPD and asthma maintenance therapy. The Company
is also exploring the potential of the drug in different diseases, such as
cystic fibrosis, where it is in pre-clinical testing and has received a Venture
and Innovation Award from the Cystic Fibrosis Trust.